Фармакоэкономика (Mar 2015)

COST EFFECTIVENESS OF ORAL PERICALCITOL IN PATIENTS WITH STAGE III-IV CHRONIC KIDNEY DISEASE AND SECONDARY HYPERPARATHYREOSIS

  • A. V. Rudakova

Journal volume & issue
Vol. 5, no. 2
pp. 13 – 16

Abstract

Read online

results of clinical trials demonstrate that selective vitamin D receptor agonist paricalcitoldecreases proteinuria in patients with chronic kidney disease (CKD) and hyperparathyreosis.

Keywords